STANT

STANT b.v. is developing novel therapeutics modulating the STING pathway with potential for the treatment of autoimmune, inflammatory, cardiovascular, metabolic and neurodegenerative diseases. The STING pathway is the body’s master regulator of immune responses to mislocalized or abnormal DNA. During disease pathology, diverse mechanisms cause DNA to be released and to activate the STING pathway, thereby inducing inflammatory mechanisms as well as cell death and autophagy.

Based on new insights identified by Søren R. Paludan and Sonia Assil, STANT is advancing proprietary compounds that block the STING pathway with a differentiated mode of action. These inhibitors are designed to block the ongoing, perpetual cycle of inflammation amplified following tissue and organ damage and may be used to treat diseases such as systemic lupus erythematosus (SLE), cardiovascular diseases, amyotrophic lateral sclerosis (ALS), Parkinson and chronic inflammatory diseases such as kidney disease.